ScottMSchuetzeMDPhD

Oncology • Ann Arbor, MI

Hematologic Oncology, Sarcoma

Professor, Internal Medicine, University of Michigan Medical School

Join to view full profile

Dr. Schuetze is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Schuetze's full profile

Already have an account?

Office
1500 East Medical Center Dr
B1 floor Cancer Recp C
Ann Arbor, MI 48109
Phone+1 734-647-8902

Education & Training

University of WashingtonFellowship, Hematology and Medical Oncology, 1996 - 1999
Duke University HospitalResidency, Internal Medicine, 1993 - 1996
Oregon Health and Science University School of MedicineClass of 1993

Certifications & Licensure

MI State Medical License 2004 - 2026
NC State Medical License 1993 - 1999
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Clinical Trials

S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor Start of enrollment: 2003 Dec 01
Completed
Phase 2
Imatinib Mesylate in Treating Patients With Locally Recurrent or Metastatic Dermatofibrosarcoma Protuberans Start of enrollment: 2004 May 01
Completed
Phase 2
Evaluation of Side Effects and Relative Activity of Two Chemotherapy Regimens in the Treatment Soft Tissue Sarcoma Start of enrollment: 2004 Aug 01
Completed
Phase 2
Neoadjuvant Imatinib in Dermatofibrosarcoma Protuberans Start of enrollment: 2006 May 01
Completed
Phase 2
Trial of Dasatinib in Advanced Sarcomas Start of enrollment: 2007 May 01
Completed
Phase 2
A Phase II Study of Oral Cyclophosphamide and Sirolimus (OCR) in Advanced Sarcoma Start of enrollment: 2008 Aug 01
Completed
Phase 2
Pazopanib Hydrochloride in Treating Patients With Advanced Angiosarcoma Start of enrollment: 2011 Nov 03
Completed
Phase 2
A Phase II Trial Comparing Gemcitabine and Pazopanib Versus Gemcitabine and Docetaxel for Patients With Advanced Soft Tissue Sarcoma Start of enrollment: 2012 Sep 27
Completed
Phase 2
Safety Study of Intratumoral Injection of Clostridium Novyi-NT Spores to Treat Patients With Solid Tumors That Have Not Responded to Standard Therapies Start of enrollment: 2013 Oct 01
Completed
Phase 1
Phase 3 Study to Treat Patients With Soft Tissue Sarcomas Start of enrollment: 2014 Jan 01
Completed
Phase 3
A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma Start of enrollment: 2015 Sep 14
COMPLETED
PHASE3
Letetresgene Autoleucel Engineered T Cells in NY-ESO-1 Positive Participants With Advanced Myxoid/ Round Cell Liposarcoma Start of enrollment: 2016 Dec 06
Completed
Phase 2
Trametinib in Treating Patients With Epithelioid Hemangioendothelioma That is Metastatic, Locally Advanced, or Cannot Be Removed by Surgery Start of enrollment: 2017 Jun 20
COMPLETED
PHASE2
Localized Leiomyosarcoma Biomarker Protocol Start of enrollment: 2023 Apr 26
RECRUITING
Roles: Contact, Principal Investigator
Open-Label Study of the CDK4/6 Inhibitor SPH4336 in Subjects With Locally Advanced or Metastatic Liposarcomas Start of enrollment: 2023 Aug 31
TERMINATED
PHASE2
Roles: Contact
Metastatic Leiomyosarcoma Biomarker Protocol Start of enrollment: 2022 Dec 22
RECRUITING
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

Letetresgene Autoleucel in Advanced/Metastatic Myxoid/Round Cell Liposarcoma.
Sandra P D'Angelo, Mihaela Druta, Brian A Van Tine, David Liebner, Scott M Schuetze
Journal of Clinical Oncology. 2025-01-21
2 citations
Safety and efficacy of pembrolizumab, radiation therapy, and surgery versus radiation therapy and surgery for stage III soft tissue sarcoma of the extremity (SU2C-SARC...
Yvonne M Mowery, Karla V Ballman, Angela M Hong, Scott M Schuetze, Andrew J Wagner
Lancet. 2024-11-23
5 citations
A Single-Arm Phase 2 Trial of Trametinib in Patients with Locally Advanced or Metastatic Epithelioid Hemangioendothelioma.
Scott M Schuetze, Karla V Ballman, Rachel Heise, Kristen N Ganjoo, Elizabeth J Davis
Clinical Cancer Research. 2024-10-15

Journal Articles

Assessment of Clinical Benefit of Integrative Genomic Profiling in Advanced Solid Tumors
Erin F Cobain, Francis Worden, Scott M Schuetze, Mark M Zalupski, Vaibhav Sahai, Ajjai Alva, Anne F Schott, Moshe Talpaz, JAMA Oncology
Efficacy and Tolerability of Trabectedin in Elderly Patients with Sarcoma: Subgroup Analysis from a Phase 3, Randomized Controlled Study of Trabectedin or Dacarbazine ...
A Elias, M Milhem, S Patel, S M Schuetze, M L Hensley, Annals of Oncology

Press Mentions

AHA News: Cancers of the Heart Are Rare -- and Here's WhyFebruary 25th, 2019
Liposarcoma, Rare Cancer That Took Rob Ford’s Life, Hard to Treat: OncologistMarch 22nd, 2016

Grant Support

Genetics and Genomics of Leiomyosarcoma (LMS): Improved understanding of cancer biology and new approaches to diagnosis and treatmentUNIVERSITY OF MICHIGAN AT ANN ARBOR2022–2027
Early Phase Clinical Cancer Prevention ConsortiumUNIVERSITY OF MICHIGAN AT ANN ARBOR2020–2025